June 2nd 2023
Using the Modified Fatigue Impact Scale, patients either forced to exercise or who volunteered saw significant improvements over a 12-week period.
June 2nd 2023
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
Applying Precision Medicine: Improving Care for Patients with Motor Complications of Parkinson Disease
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
BURST CME™: Taking ALS Management to the Next Level
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease
Mindfulness-Based Stress Reduction Intervention Shows Potential to Treat Silent Symptoms of Multiple SclerosisJune 1st 2023
In mixed-effect analyses adjusting for multiple cofounders, changes in inflammatory gene expression correlated inversely with changes in patient-reported stress, loneliness, hair cortisol, and aspects of interoceptive awareness.
CMS Announces Plan to Provide Coverage of Antiamyloid Therapies for Alzheimer DiseaseJune 1st 2023
In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.
Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis: Recent UpdatesMay 31st 2023
In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]
NeuroVoices: Cornelia Drees, MD, on Understanding the Different Advantages of Microburst Vagus Nerve StimulationMay 31st 2023
Cornelia Drees, MD, senior associate consultant, Department of Neurology, Mayo Clinic, discussed the potential of microburst vagus nerve stimulation as a more targeted treatment for drug-resistant epilepsy.
World MS Day: Cognitive Function in Multiple SclerosisMay 30th 2023
In recognition of World MS Day, Meghan Beier, PhD, MA, a health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine, discussed the effects of multiple sclerosis (MS) on cognitive function.
Stress May Play Role in Multiple Sclerosis Disability, Study SuggestsMay 30th 2023
The research, which highlighted stressors occurring in both childhood and adult stages contributing to MS disability, could inform conversations regarding stress reduction techniques for patients with MS.
Enrollment for Phase 3 INTUNE Study of Pitolisant in Idiopathic Hypersomnia Ahead of ScheduleMay 29th 2023
Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.
NeurologyLive® Clinician of the Month Spotlight: Andrew Russman, DOMay 28th 2023
As part of our monthly clinician spotlight, NeurologyLive® highlighted stroke expert Andrew Russman, DO, head of the Stroke Program and medical director of the Comprehensive Stroke Center at Cleveland Clinic.
Vatiquinone Shows Additional Benefits on Friedreich Ataxia Disease Progression Despite Failing to Meet Primary End PointMay 27th 2023
Over a 72-week treatment period, vatiquinone showed significant impacts on bulbar and upright stability subscales of the modified Friedreich Ataxia Rating Scale score.